GlobeNewswire Clinical StudiesOriginal article
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
Phase 3positiveinfigratinibPositive
AI Analysis
Summary
Oral infigratinib demonstrated favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media in the Phase 3 PROPEL 3 trial at 52 weeks in children with achondroplasia.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Favorable trends against placebo in exploratory endpoints including sleep apnea and otitis media events at 52 weeks
Importance:6/10
Sentiment:
0.65
achondroplasiarare diseasepediatricPhase 3exploratory endpoints
Read the original article
Published by GlobeNewswire Clinical Studies on September 9, 2026 8:00 AM